Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

apy or Hematopoietic Stem Cell Transplantation [Abstract 673]

Research suggests that a new targeted therapy, quizartinib, may be a safe and effective option to treat a subset of patients with treatment-resistant acute myeloid leukemia (AML).

AML is a fast-growing blood cancer in which patients produce an excessive amount of abnormal, immature white blood cells that are unable to adequately fight infection. Following AML diagnosis, leukemia cells from patients undergo genetic testing to identify the mutation driving the disease, which helps determine the appropriate treatment protocol. Of the many types of genetic mutations that can occur in AML, one of the most threatening is the FLT3-ITD (internal tandem duplication), which makes the leukemia even more aggressive and typically leads to failure of standard chemotherapy treatment response.

"The FLT3 mutation is essentially a power switch that leukemia cells use to spread more aggressively, which helps them to grow back immediately after chemotherapy," said Mark J. Levis, MD, PhD, lead author and Associate Professor of Oncology, Pharmacology, and Medicine at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine in Baltimore. "The only way to treat this type of mutation is to find a way to turn the switch off a feat that has eluded researchers for far too long."

Patients with the FLT3-ITD mutation can achieve remission with standard chemotherapy but tend to relapse very quickly. An important treatment option is a stem cell transplant, but only if the patient is in some form of remission; otherwise, transplant failure rates are high. Given the barriers to treatment in this patient population, researchers have been examining the efficacy of the investigational oral agent quizartinib, which is designed to "turn off" the mutated FLT3 enzyme, thus forcing the immature cancer c
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge youths ... towards the goal for a better future for all ... smaller groups will be held after the conference with ... Healthcare, Social and Volunteerism, Women and Youth Empowerment, to ... , Young adults aged between 18-30 years that have ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... 2015 Gerald “Solutionman” Haman surveyed over ... barriers to innovative thinking. “The #1 block was ... of tools,” reports Haman, who created the Thinkubator Innovation ... people felt that they did not have enough time ... resources to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2
... Offerings to Help Hospitals Prevent Infections, DUBLIN, ... of products and services that improve the safety ... agreement to,acquire the assets of privately held Enturia ... leading line of infection prevention,products sold under the ...
... Organizations Levy Coinsurance, Charges and Other Protocols ... ... Report from Decision Resources, WALTHAM, Mass., March ... and advisory firms for pharmaceutical and,healthcare issues, finds that ...
... Begin Today at 9:00 a.m. ET -, VALENCIA, ... today reported financial results for the fourth,quarter and year ... of 2007, total operating expenses were $79.1,million, compared to ... development (R&D) expenses increased by $7.0 million to $66.8 ...
... March 4 Crdentia Corp. (OTC Bulletin,Board: ... staffing services,today announced the appointment of Mr. ... and Chief Clinical Officer. In this newly ... regulatory compliance and accreditation, assisting in business,plan ...
... 2007 Total Revenue Increased 46.1%, Net Income Rose ... Simcere Pharmaceutical,Group (NYSE: SCR ), a leading ... and supplier of the patented anti-cancer,product Endu in ... ended December 31, 2007 and fiscal year ended ...
... , - Online Resource to Support ... the world-leading publisher of scientific, technical and,medical ... launch of,its Publishing Ethics Resource Kit (PERK),( ... Elsevier Editors, Conference in Singapore, Mark,Seeley, Senior ...
Cached Medicine News:Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 2Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 3Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 4Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 5Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 6Health News:Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 2Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 14Health News:Elsevier Launches Publishing Ethics Resource Kit 2
(Date:2/27/2015)... , Feb. 27, 2015 Pharmaceutical and biotech ... multiple products for the same indication. This can be ... want to prevent one of their brands from gaining ... According to recent research by benchmarking firm, Best Practices, ... independent brands rather than together as part of a ...
(Date:2/27/2015)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: VTAE ).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On February 27, 2015, the Company announced that its ...
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... has named Neogen Corporation (Nasdaq: NEOG ) to its ... ninth time in the last 11 years, and the sixth consecutive ... recognition of our company,s solid performance, and especially when it comes ... CEO. "Companies must clear a series of tough hurdles in order ...
... Life Sciences, Inc. (Nasdaq: CALP ) today ... ILMN ) for Caliper,s LabChip ® XT ... control platform. These systems are automated alternatives to traditional ... and assessment. The LabChip platforms provide Genome Analyzer and ...
Cached Medicine Technology:Neogen Again Named to Forbes' List of Best Small Companies 2Caliper Life Sciences Signs Co-Marketing Pact with Illumina to Improve Sequencing Workflows 2
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: